IISER MOHALI

Abstract: The discovery of Bedaquiline has marked a turning point in the fight against drug-resistant tuberculosis (DR-TB), offering new hope where traditional treatments have failed. This presentation explores Bedaquiline’s transformative impact on the global TB landscape while addressing the critical concern of emerging resistance. We will also examine the essential characteristics of target product profiles for future regimens and explore the innovative pipeline of next-generation therapies. Can these advancements bring us closer to a world free of TB? Join us as we envision the path forward in TB elimination.